Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised
Retrieved on:
Martedì, Gennaio 2, 2024
Marketing, Plasma protein binding, Constipation, INN, Risk, Hypotension, Hypertension, Fatigue, Nausea, Cancer, Inflammation, Tachypnea, Back pain, Chest pain, Diagnosis, Anatomy, Cough, IIA, CHMP, Chills, Diarrhea, Fever, ATC, Pain, European, Disease, Ageing, Weakness, Nonsteroidal anti-inflammatory drug, Human, Tachycardia, Anemia, Arthralgia, Medical Subject Headings, European Commission, Immune system, International, Language, Somatic symptom disorder, Myalgia, Dizziness, Monocyte, Select, Patient, Medicine, Hyperhidrosis, Vomiting, Allergy, Headache, Mifamurtide, Macrophage, Abdominal pain, Hypothermia, Chronic pain, Safety, Committee, Periodic breathing, Medical device
Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised
Key Points:
Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 20, Status: Authorised